Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: Effects on linear growth and body disproportion

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 12, 2011, Pages

  Živičnjak, Miroslav ^a   Schnabel, D ^b   Staude, H ^c   Even, G ^d   Marx, M ^e   Beetz, R ^f   Holder, M ^g   Billing, H ^h   Fischer, D C ^a   Rabl, W ⁱ   Schumacher, M ^j   Hiort, O ^j   Haffner, D ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g OLGAHOSPITAL   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; GROWTH HORMONE; PARATHYROID HORMONE; PHOSPHATASE; PHOSPHATE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ABSENCE OF SIDE EFFECTS; ARTICLE; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BONE BOWING; BONE MATURATION; CHILD; COHORT ANALYSIS; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TOLERABILITY; FEMALE; FGF23; FRAMESHIFT MUTATION; GENE; GENETIC ANALYSIS; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; OPEN STUDY; OUTCOME ASSESSMENT; PHEX GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBERTY; RANDOMIZED CONTROLLED TRIAL; SAFETY; SCORING SYSTEM; X LINKED HYPOPHOSPHATEMIC RICKETS;

BODY HEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 83155177077     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0399     Document Type: Article

References (52)

1. Alon US 2006 Hypophosphatemic vitamin-D resistant rickets. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, DC: American Society of Bone and Mineral Research; 342-345
2. Bastepe M, Jüppner H 2008 Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord 9:171-180
3. Gaucher C, Walrant-Debray O, Nguyen TM, Esterle L, Garabédian M, Jehan F 2009 PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. Hum Genet 125:401-411
4. HYP Consortium 1995 A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11:130-136
5. Ichikawa S, Traxler EA, Estwick SA, Curry LR, Johnson ML, Sorenson AH, Imel EA, Econs MJ 2008 Mutational survey of the PHEX gene in patients with X-linked hypophosphatemic rickets. Bone 43:663-666
6. Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, Fujita T, Wada M, Yamashita T, Fukumoto S, Shimada T 2009 Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 24:1879-1888
7. Jan de Beur SM, Levine MA 2002 Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metab 87:2467-2473 (Pubitemid 34655302)
8. Strom TM, Jüppner H 2008 PHEX, FGF23, DMP1 and beyond. Curr Opin Nephrol Hypertens 17:357-362
9. Kooh SW, Binet A, Daneman A 1994 Nephrocalcinosis in X-linked hypophosphataemic rickets: its relationship to treatment, kidney function, and growth. Clin Invest Med 17:123-130 (Pubitemid 24167319)
10. Patzer L, van't Hoff W, Shah V, Hallson P, Kasidas GP, Samuell C, de Bruyn R, Barratt TM, Dillon MJ 1999 Urinary supersaturation of calcium oxalate and phosphate in patients with X-linked hypophosphatemic rickets and in healthy schoolchildren. J Pediatr 135:611-617 (Pubitemid 30180452)
11. Reusz GS, Latta K, Hoyer PF, Byrd DJ, Ehrich JH, Brodehl J 1990 Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated hypophosphataemic rickets. Lancet 335:1240-1243 (Pubitemid 20181781)
12. Schmitt CP, Mehls O 2004 The enigma of hyperparathyroidism in hypophosphatemic rickets. Pediatr Nephrol 19:473-477 (Pubitemid 38594282)
13. Ariceta G, Langman CB 2007 Growth in X-linked hypophosphatemic rickets. Eur J Pediatr 166:303-309 (Pubitemid 46295097)
14. Friedman NE, Lobaugh B, Drezner MK 1993 Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 76:839-844 (Pubitemid 23110824)
15. Haffner D, Weinfurth A, Manz F, Schmidt H, Bremer HJ, Mehls O, Schärer K 1999 Long-term outcome of paediatric patients with hereditary tubular disorders. Nephron 83:250-260 (Pubitemid 29486404)
16. Steendijk R, Hauspie RC 1992 The pattern of growth and growth retardation of patients with hypophosphataemic vitamin D-resistant rickets: a longitudinal study. Eur J Pediatr 151:422-427
17. Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M 1991 Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325:1843-1848
18. Ziviènjak M, Schnabel D, Billing H, Staude H, Filler G, Querfeld U, Schumacher M, Pyper A, Schröder C, Brämswig J, Haffner D 2011 Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol 26:223-231
19. Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G 2001 Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 138:236-243 (Pubitemid 32156440)
20. Haffner D, Wühl E, Blum WF, Schaefer F, Mehls O 1995 Disproportionate growth following long-term growth hormone treatment in short children with X-linked hypophosphataemia. Eur J Pediatr 154:610-613
21. Haffner D, Nissel R, Wühl E, Mehls O 2004 Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics 113:e593-596
22. Reusz GS, Miltényi G, Stubnya G, Szabó A, Horváth C, Byrd DJ, Péter F, Tulassay T 1997 X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone. Pediatr Nephrol 11:573-577 (Pubitemid 27397086)
23. Saggese G, Baroncelli GI, Bertelloni S, Perri G 1995 Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density. J Pediatr 127:395-402
24. Seikaly MG, Brown R, Baum M 1997 The effect of recombinant human growth hormone in children with X-linked hypophosphatemia. Pediatrics 100:879-884 (Pubitemid 27463326)
25. Petersen DJ, Boniface AM, Schranck FW, Rupich RC, Whyte MP 1992 X-linked hypophosphatemic rickets: a study (with literature review) of linear growth response to calcitriol and phosphate therapy. J Bone Miner Res 7:583-597
26. Reusz GS, Hoyer PF, Lucas M, Krohn HP, Ehrich JH, Brodehl J 1990 X linked hypophosphataemia: treatment, height gain, and nephrocalcinosis. Arch Dis Child 65:1125-1128 (Pubitemid 20330963)
27. Hoyer PF 2004 Nephrokalzinose. In: Hofmann V, Deeg KH, Hoyer PF, eds. Ultraschall-diagnostik in Pädiatrie und Kinderchirurgie. Stuttgart, Germany, and New York: Thieme; 467-470
28. Greulich WW, Pyle SI 1959 Radiographic atlas of skeletal development of the hand and wrist. Standford, CA: Stanford University Press
29. Brodehl J, Krause A, Hoyer PF 1988 Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol 2:183-189
30. Schwartz GJ, Haycock GB, Edelmann Jr CM, Spitzer A 1976 A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259-263
31. Weiner JS, Lourie JA 1981 Practical human biology. London: Academic Press
32. Zivicnjak M, Naranciæ NS, Szirovicza L, Franke D, Hrenoviæ J, Bisof V 2003 Gender-specific growth patterns for stature, sitting height and limbs length in Croatian children and youth (3 to 18 years of age). Coll Antropol 27:321-334 (Pubitemid 38376547)
33. Zivicnjak M, Franke D, Filler G, Haffner D, Froede K, Nissel R, Haase S, Offner G, Ehrich JH, Querfeld U 2007 Growth impairment shows an age-dependent pattern in boys with chronic kidney disease. Pediatr Nephrol 22:420-429 (Pubitemid 46772760)
34. Zivicnjak M, Smolej Naranciæ N, Szirovicza L, Franke D, Hrenoviæ J, Bisof V, Tomas Z, Skariæ-Juriæ T 2008 Gender-specific growth patterns of transversal body dimensions in Croatian children and youth (2 to 18 years of age). Coll Antropol 32:419-431
35. Molinari L, Largo RH, Prader A 1985 Target height and secular trend in the Swiss population. In: Borms J, Hauspie R, Sand A, Susanne C, Habbelinck M, eds. Human growth and development. New York: Plenum Press; 193-200
36. Francis F, Strom TM, Hennig S, Böddrich A, Lorenz B, Brandau O, Mohnike KL, Cagnoli M, Steffens C, Klages S, Borzym K, Pohl T, Oudet C, Econs MJ, Rowe PS, Reinhardt R, Meitinger T, Lehrach H 1997 Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets. Genome Res 7:573-585 (Pubitemid 27313606)
37. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE 2005 A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424-2427 (Pubitemid 40586293)
38. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G 2002 Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57
39. Auron A, Alon US 2005 Resolution of medullary nephrocalcinosis in children with metabolic bone disorders. Pediatr Nephrol 20:1143-1145 (Pubitemid 41001557)
40. Zivicnjak M, Franke D, Ehrich JH, Filler G 2000 Does growth hormone therapy harmonize distorted morphology and body composition in chronic renal failure? Pediatr Nephrol 15:229-235
41. Caverzasio J, Bonjour JP 1996 Characteristics and regulation of Pi transport in osteogenic cells for bone metabolism. Kidney Int 49:975-980 (Pubitemid 26122700)
42. Hirschberg R 1996 Insulin-like growth factor I in the kidney. Miner Electrolyte Metab 22:128-132 (Pubitemid 126448822)
43. 3 production in hypophysectomized rats. Eur J Endocrinol 146:97-105
44. Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ 2010 Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 95:1846-1850
45. Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM 2010 Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 95:E352-E357
46. Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD 2008 Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 3:658-664
47. Raeder H, Shaw N, Netelenbos C, Bjerknes R 2008 A case of Xlinked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. Eur J Endocrinol 159(Suppl 1):S101-S105
48. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566 (Pubitemid 28067285)
49. Cohen P, Clemmons DR, Rosenfeld RG 2000 Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 10:297-305 (Pubitemid 32125100)
50. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625 (Pubitemid 29194048)
51. Shim M, Cohen P 1999 IGFs and human cancer: implications regarding the risk of growth hormone therapy. Horm Res 51(Suppl 3):42-51
52. European Medicines Agency 2010 Update on somatropin-containing medicines EMA/CHMP/820649/2010. London: European Medicines Agency